| Name | Title | Contact Details |
|---|---|---|
Maris Harrington |
Director of Philanthropy | Profile |
We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
IriSys Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lucid Hearing hearing aids are affordable and ensure that you hear what you need to hear when you need to hear it. Come to one of our 500+ hearing centers nationwide and receive a free hearing test today.
Follow us for career advice, news & jobs. Find your Formula for Success at Jubilant Pharma! Subsidiaries: HollisterStier, Cadista, Radiopharma, and JGL.